TFE3-translocated PEComas are less responsive to mTOR inhibitors (21), and the low response rate is associated with MET pathway activation, which is one of the mechanisms of mTOR inhibitor resistance. The gene discussed is MET; the disease is neoplasm with perivascular epithelioid cell differentiation.